DrugPatentWatch Database Preview
INVELTYS Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Inveltys patents expire, and what generic alternatives are available?
Inveltys is a drug marketed by Kala Pharms Inc and is included in one NDA. There are six patents protecting this drug.
This drug has forty-six patent family members in twelve countries.
The generic ingredient in INVELTYS is loteprednol etabonate. There are ten drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
US ANDA Litigation and Generic Entry Outlook for Inveltys
A generic version of INVELTYS was approved as loteprednol etabonate by HI TECH on April 17th, 2019.
Summary for INVELTYS
| International Patents: | 46 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 45 |
| Patent Applications: | 2,322 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for INVELTYS |
| DailyMed Link: | INVELTYS at DailyMed |
Synonyms for INVELTYS
| 034L466 |
| 82034-46-6 |
| AB00698349_08 |
| AB00698349-05 |
| AB00698349-07 |
| AB2000207 |
| AC1L9FKJ |
| AKOS005145741 |
| Alrex |
| Alrex;Lotemax |
| Androsta-1,4-diene-17-carboxylic acid, 17-((ethoxycarbonyl)oxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11beta,17alpha)- |
| BCP28645 |
| C24H31ClO7 |
| CAS-82034-46-6 |
| CCG-101041 |
| CDDD 5604 |
| CDDD-5604 |
| CHEBI:31784 |
| CHEMBL1200865 |
| chloromethyl (1S,2R,10S,11S,14R,15S,17S)-14-[(ethoxycarbonyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-14-carboxylate |
| chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-((ethoxycarbonyl)oxy)-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carb |
| chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate |
| Chloromethyl 11beta,17-dihydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate, 17-(ethyl carbonate) |
| chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate |
| CS-0900 |
| D01689 |
| DMKSVUSAATWOCU-HROMYWEYSA-N |
| DSSTox_CID_26468 |
| DSSTox_GSID_46468 |
| DSSTox_RID_81641 |
| DTXSID2046468 |
| GS-3599 |
| GTPL7085 |
| HGP 1 |
| HGP-1 |
| HMS2051F16 |
| HMS2232J09 |
| HMS3715N06 |
| HY-17358 |
| IDR-90102 |
| IDR-90103 |
| K462 |
| Locort |
| Loteflam |
| Lotemax |
| Lotemax (TN) |
| Loteprednol etabonate |
| Loteprednol etabonate (JAN/USAN) |
| Loteprednol etabonate [USAN:JAN] |
| Loteprednol etabonate Opphthalmic suspension |
| Loteprednol Etabonate, >=98% (HPLC) |
| Loteprednol-etabonate |
| Loterox |
| MLS001424221 |
| NC00291 |
| NCGC00164594-01 |
| NCGC00164594-02 |
| P 5604 |
| P-5604 |
| s1669 |
| SCHEMBL23907 |
| SMR000469178 |
| ST24030829 |
| Tox21_112219 |
| Tox21_112219_1 |
| UNII-YEH1EZ96K6 |
| YEH1EZ96K6 |
| ZINC3920673 |
US Patents and Regulatory Information for INVELTYS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kala Pharms Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Kala Pharms Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Kala Pharms Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Kala Pharms Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for INVELTYS
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 112014027296 | Start Trial |
| South Korea | 20150006869 | Start Trial |
| New Zealand | 742005 | Start Trial |
| New Zealand | 700875 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
